Login to Your Account



Vivus to Beat Arena to Market?

Qsymia Set for Fourth-Quarter Launch with Reasonable REMS

By Catherine Shaffer
Staff Writer

Thursday, July 19, 2012

Vivus Inc. shared details of its launch plans and risk evaluation and management strategy (REMS) for newly approved weight loss drug Qsymia (phentermine/topiramate) on an investor call Wednesday morning. Vivus is aiming for a fourth-quarter launch with a REMS that includes a medication guide delivered with each prescription, a health provider training program and distribution of the drug through certified pharmacies only.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription